Who is sponsoring NCT03420235?

NCT03420235 is sponsored by Erasmus Medical Center.

What drugs are being tested in NCT03420235?

Interventions in NCT03420235: Home monitoring program.

What condition does NCT03420235 study?

NCT03420235 studies Idiopathic Pulmonary Fibrosis.

Is NCT03420235 still recruiting?

NCT03420235 is currently completed. Last updated 30 January 2020.

Last reviewed 2020-01-30 · How we verify

NCT03420235

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of Life

Completed NA Last updated 30 January 2020

What this trial tests

NA trial testing Home monitoring program in Idiopathic Pulmonary Fibrosis in 90 participants. Completed in 26 August 2019.

Timeline

9 January 2018

Primary endpoint
26 August 2019

26 August 2019

Quick facts

Lead sponsor	Erasmus Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	9 January 2018
Primary completion	26 August 2019
Estimated completion	26 August 2019
Sites	1 location across Netherlands

Drugs / interventions tested

Home monitoring program

Conditions studied

Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →

Sponsor

Erasmus Medical Center

Who can join

18 and older, any sex, with Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study it will be investigate whether a home monitoring program improves disease-specific health-related quality of life (HRQOL) for patients with idiopathic pulmonary fibrosis (IPF) through appropriate medication use and subsequently results in better objective and subjective outcomes.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial.
Moor CC, Mostard RLM, Grutters JC, Bresser P, et al · · 2020 · cited 102× · PMID 32325005 · DOI 10.1164/rccm.202002-0328oc
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.
Moor CC, Mostard RLM, Grutters JC, Bresser P, et al · · 2020 · cited 16× · PMID 32703201 · DOI 10.1186/s12931-020-01458-1
Digital health technology use in clinical trials of rare diseases: a systematic review.
Mao X, Zeng D, Wang X, Pearce DA, et al · · 2025 · cited 1× · PMID 41174062 · DOI 10.1038/s43856-025-01137-6

Verify or expand the search:

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting

Other Erasmus Medical Center trials

Trials by the same sponsor.

NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03420235 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
Last refreshed: 30 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03420235.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing